Solriamfetol

Solriamfetol
Clinical data
Trade names	Sunosi
Other names	SKL-N05, ADX-N05, ARL-N05, YKP10A, R228060, and JZP-110; (R)-2-amino-3-phenylpropylcarbamate hydrochloride
AHFS/Drugs.com	Monograph
MedlinePlus	a619040
License data	US DailyMed: Solriamfetol;
Routes of; administration	By mouth
Drug class	Norepinephrine–dopamine reuptake inhibitors; Wakefulness-promoting agents; Psychostimulants
ATC code	N06BA14 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: Schedule IV; EU: Rx-only;
Pharmacokinetic data
Bioavailability	~95%
Protein binding	13.3–19.4%
Metabolism	Minimal (~1%)
Metabolites	• N-Acetylsolriamfetol (~1%)
Elimination half-life	~7.1 hours
Excretion	Urine (95% unchanged)
Identifiers
	IUPAC name (2R)-2-Amino-3-phenylpropyl carbamate;
CAS Number	178429-62-4;
PubChem CID	10130337;
IUPHAR/BPS	10342;
DrugBank	DB14754;
ChemSpider	8305853;
UNII	939U7C91AI;
KEGG	D11315; as HCl: D11328;
ChEMBL	ChEMBL4297620;
CompTox Dashboard (EPA)	DTXSID401027926 ;
Chemical and physical data
Formula	C10H14N2O2
Molar mass	194.234 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC=C(C=C1)C[C@H](COC(=O)N)N;
	InChI InChI=1S/C10H14N2O2/c11-9(7-14-10(12)13)6-8-4-2-1-3-5-8/h1-5,9H,6-7,11H2,(H2,12,13)/t9-/m1/s1; Key:UCTRAOBQFUDCSR-SECBINFHSA-N;

Solriamfetol, sold under the brand name Sunosi, is a wakefulness-promoting medication used in the treatment of excessive sleepiness related to narcolepsy and sleep apnea.^[1]^[5]^[6] It is taken by mouth.^[1]

Common side effects of solriamfetol include headache, nausea, anxiety, and trouble sleeping.^[1] It is a norepinephrine–dopamine reuptake inhibitor (NDRI) and is thought to work by increasing levels of the neurotransmitters norepinephrine and dopamine in the brain.^[1]^[5] Solriamfetol has also been found to act as a TAAR1 agonist, an action that may also be involved in its effects.^[7]

The drug was discovered by a subsidiary of SK Group, which licensed rights outside of eleven countries in Asia to Aerial Pharma in 2011.^[8] In addition to its approved indication of excessive sleepiness, solriamfetol is under development for certain other uses including the treatment of attention deficit hyperactivity disorder (ADHD), binge eating disorder, and circadian rhythm sleep disorders.^[9]

^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k "Sunosi – solriamfetol tablet, film coated". DailyMed. 16 October 2019. Retrieved 24 November 2019.
^ "Summary Basis of Decision (SBD) for Sunosi". Health Canada. 23 October 2014. Retrieved 29 May 2022.
^ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada. 3 August 2022. Retrieved 25 March 2024.
^ Cite error: The named reference Sunosi EPAR was invoked but never defined (see the help page).
^ ^a ^b Powell J, Piszczatoski C, Garland S (October 2020). "Solriamfetol for Excessive Sleepiness in Narcolepsy and Obstructive Sleep Apnea". Ann Pharmacother. 54 (10): 1016–1020. doi:10.1177/1060028020915537. PMID 32270686. S2CID 215605290.
^ Abad VC, Guilleminault C (December 2018). "Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea". Expert Rev Respir Med. 12 (12): 1007–1019. doi:10.1080/17476348.2018.1541742. PMID 30365900. S2CID 53106520.
^ Cite error: The named reference GursahaniJolasMartin2023 was invoked but never defined (see the help page).
^ Ji-young S (5 March 2018). "SK Biopharmaceuticals' narcolepsy drug on track to hitting US market". The Korea Herald.
^ Cite error: The named reference AdisInsight was invoked but never defined (see the help page).